Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8IWL1
UPID:
SFPA2_HUMAN
Alternative names:
35 kDa pulmonary surfactant-associated protein; Alveolar proteinosis protein; Collectin-5
Alternative UPACC:
Q8IWL1; A4QPA7; B2RXI6; B2RXK9; C9J9I7; E3VLC6; E3VLC7; E3VLC8; E3VLC9; P07714; Q14DV3; Q5RIR8; Q5RIR9
Background:
Pulmonary surfactant-associated protein A2, also known as Collectin-5, plays a crucial role in respiratory function. It binds to surfactant phospholipids in the presence of calcium ions, significantly reducing surface tension in the alveoli, which is vital for normal breathing.
Therapeutic significance:
The protein's involvement in Interstitial lung disease 2, a condition marked by progressive lung tissue remodeling, underscores its potential as a target for therapeutic intervention. Understanding the role of Pulmonary surfactant-associated protein A2 could open doors to potential therapeutic strategies.